163 related articles for article (PubMed ID: 30055114)
1. Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.
Westermarck J
FEBS J; 2018 Nov; 285(22):4139-4145. PubMed ID: 30055114
[TBL] [Abstract][Full Text] [Related]
2. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
3. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
[TBL] [Abstract][Full Text] [Related]
5. Druggable cancer phosphatases.
Vainonen JP; Momeny M; Westermarck J
Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827975
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of PP2A.
O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A: a target for anticancer therapy.
Perrotti D; Neviani P
Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
[TBL] [Abstract][Full Text] [Related]
8. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
[TBL] [Abstract][Full Text] [Related]
9. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Westermarck J; Hahn WC
Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
[TBL] [Abstract][Full Text] [Related]
10. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
11. The role of PP2A A subunits in tumor suppression.
Sablina AA; Hahn WC
Cell Adh Migr; 2007; 1(3):140-1. PubMed ID: 19262135
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
Remmerie M; Janssens V
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104481
[TBL] [Abstract][Full Text] [Related]
13. Targeting PP2A in cancer: Combination therapies.
Mazhar S; Taylor SE; Sangodkar J; Narla G
Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):51-63. PubMed ID: 30401535
[TBL] [Abstract][Full Text] [Related]
14. Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1.
Kaur A; Westermarck J
Biochem Soc Trans; 2016 Dec; 44(6):1683-1693. PubMed ID: 27913678
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
16. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
Kauko O; Westermarck J
Int J Biochem Cell Biol; 2018 Mar; 96():157-164. PubMed ID: 29355757
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
[TBL] [Abstract][Full Text] [Related]
19. PP2A: unveiling a reluctant tumor suppressor.
Mumby M
Cell; 2007 Jul; 130(1):21-4. PubMed ID: 17632053
[TBL] [Abstract][Full Text] [Related]
20. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
